New drug superior to tamoxifen in blocking return of breast cancer

12/10/2004 | Wall Street Journal, The

AstraZeneca's Arimidex has shown in trials it does a much better job of preventing the recurrence of breast cancer than the popular tamoxifen, according to a study in the journal Lancet. The study, funded by AstraZeneca, said Arimidex could defend against up to 80% of the most common types of tumors that occur after menopause, compared with a 50% rate attributed to tamoxifen.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care